1. Altmann D, Eggmann U, Ammann P: Medikamentös induzierte Verlängerung des QT-Intervalls. [Drug induced QT prolongation]. Wien Klin Wochenschr 2008; 120: 128–35. CrossRef MEDLINE 2. Haverkamp H, ...

Purpose: The association of methadone with Q-T interval prolongation and torsades de pointes (TdP) is reviewed, and recommendations for preventing Q-T interval prolongation in methadone users are ...

In 1999, as the result of growing recognition of the potential for noncardiac drugs such as terfenadine or cisapride to cause QT prolongation and torsades de pointes ventricular arrhythmias, the ...

Marked prolongation of the QT interval and polymorphic ventricular tachycardia following medication (drug-induced long QT syndrome, diLQTS) is a severe adverse drug reaction (ADR) that phenocopies ...

Rockville MD - The US FDA and Johnson & Johnson have informed healthcare professionals of a revision to the prescribing information for haloperidol, an antipsychotic marketed as Haldol, Haldol ...

The QT interval on the ECG is recognized as an independent predictor of cardiac mortality and a sensitive, but relatively nonspecific, predictor of drug-induced torsades de pointes. In recent years, ...

Since its approval, there have been no cases of torsades de pointes or unexplained sudden death among US patients treated with Caprelsa.

Drug-induced ventricular tachyarrhythmias can be caused by cardiovascular drugs, noncardiovascular drugs, and even nonprescription agents. They can result in arrhythmic emergencies and sudden cardiac ...

Most men with prostate cancer who are treated with medical castration, also called androgen-deprivation therapy, will have an increase in QT interval, with torsade de pointes and ventricular ...

Torsades de pointes (French for “twisting of the points”) is one of several types of life-threatening heart rhythm disturbances. In the case of torsades de pointes (TdP), the heart’s two lower ...

The Food and Drug Administration (FDA) has approved updated labeling for Sustiva (efavirenz capsules and tablets; Bristol-Myers Squibb) to include a warning regarding QTc prolongation. The updated ...

Currently, only 10% of the drugs that enter Phase I receive marketing approval from the U.S. Food and Drug Administration (FDA), with unmanageable toxicity accounting for approximately 30% of the ...